Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (PGNY) generates a steady flow of news as a global leader in women’s health and family building solutions listed on the Nasdaq Global Select Market. Company updates frequently focus on fertility and women’s health benefits, research on employee and member needs, and financial performance, giving investors and benefits professionals insight into how Progyny’s model is evolving.
News coverage commonly includes quarterly earnings results and financial guidance, which are also referenced in the company’s Form 8-K filings. These releases discuss revenue from fertility benefit services and pharmacy benefit services, member engagement trends, client additions, and key metrics such as assisted reproductive treatment cycles and utilization rates. Investors following PGNY news can see how changes in client count, covered lives, and engagement influence the company’s reported results and outlook.
Progyny also issues news about new programs and product expansions. For example, it has announced pregnancy, postpartum, and menopause programs for global employers that complement its existing global fertility and family building offering, along with details on features such as Global Care Advocates, knowledge centers, and country-specific navigator support. These announcements provide context on how Progyny is extending its reach across the women’s health continuum and into global markets.
Another important category of news involves research and thought leadership. Progyny has released studies on men’s fertility experiences and on gaps between employee expectations and employer offerings in women’s health benefits, conducted with Dynata. These stories highlight barriers such as stigma, cost, and benefit complexity, and they underscore the company’s focus on data-driven insights for employers.
Additional news items may cover conference participation, leadership recognition, and partnerships, such as appearances at healthcare conferences and recognition of the CEO as a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health. For anyone tracking PGNY, this news page offers a centralized view of operational, financial, and strategic developments over time.
Progyny (Nasdaq: PGNY), a leader in women's health and family building solutions, announces multiple events for National Infertility Awareness Week (NIAW) and Canadian Fertility Awareness Week (CFAW) from April 20-26, 2025.
Key events include:
- April 21: Nasdaq Stock Market Opening Bell ceremony and Empire State Building lighting in orange
- April 22: 'Infertility Unfiltered' Panel Event in New York and 'Light the Night' Event in Chicago
- April 24: CN Tower lighting in green for CFAW in Toronto
The campaign features advocates Jessi and Alessio Pasini, and Demi and Tom Schweers sharing their fertility journeys. Progyny is partnering with RESOLVE: The National Infertility Association and Fertility Matters Canada to raise awareness about fertility care accessibility and reduce stigma associated with infertility, which affects one in six people trying to conceive.
Progyny (NASDAQ: PGNY) and The Broken Brown Egg have announced their fourth annual Awareness, Hope, and Activism (AHA) Grant for 2025, aimed at supporting BIPOC individuals and couples in family building. The partnership addresses systemic barriers including financial obstacles, health disparities, and social stigmas in fertility care.
Grant recipients will receive comprehensive support including:
- Financial assistance for fertility treatments
- Enhanced medication support through Alto Pharmacy with same-day delivery options
- Unlimited access to a dedicated Progyny Patient Care Advocate
- Clinical education and emotional support throughout their journey
The grant application period runs from April 8 to May 12, 2025, open to U.S. citizens and legal residents aged 18-45. Winners will be selected by a panel of BIPOC infertility advocates and physicians, with announcements scheduled for May 19.
Progyny (NASDAQ: PGNY) announces the expansion of its maternal health services by introducing doula support, both in-person and virtual. The company has partnered with Pacify, a leading maternity care solutions provider, to enhance its comprehensive maternal offerings.
The new doula services aim to address pregnancy, childbirth, and perinatal conditions, which represent a significant portion of employer health spending in the U.S. Members will be matched with specialty-trained, certified doulas based on their care needs and demographic preferences.
Research indicates that doula support may help:
- Reduce C-section rates
- Lower NICU complications
- Decrease maternal health barriers
- Improve overall birthing experience
The service is integrated into Progyny's Pregnancy and Postpartum program, offering support throughout the pregnancy journey, including prenatal care, labor support, lactation assistance, postpartum care, and miscarriage support.
Progyny (NASDAQ: PGNY) has launched its new Parent and Child Well-being offering, expanding its family building solutions portfolio. The program aims to support working parents and caregivers with comprehensive services addressing return-to-work challenges and emotional health support.
The offering comes as statistics show nearly 40% of the U.S. workforce are parents with children under 18, with 48% reporting overwhelming daily stress. The program features:
- Personalized support from licensed clinical social workers
- Benefit navigation assistance for leave planning and paperwork
- Digital tools including educational content and webinars
- Return-to-work transition support
The service is designed to enhance job satisfaction and retention while providing continuous support from preconception through early childhood development. The program is available to employers and health plans.
Progyny (Nasdaq: PGNY), a leader in fertility, family building, and women's health benefits solutions, has announced its participation in three major investor conferences in March 2025.
The company's schedule includes:
- A fireside chat at the Leerink Partners Global Healthcare Conference in Miami on March 10, 2025, at 11:20 a.m. ET
- Meetings at the Barclays 27th Annual Global Healthcare Conference in Miami on March 11, 2025
- A virtual fireside chat with CEO Pete Anevski at the KeyBanc Capital Markets Healthcare Forum on March 19, 2025, at 2:15 p.m. ET
Live audiocasts and replays of the fireside chats will be accessible through Progyny's investor relations website at investors.progyny.com.
Progyny (NASDAQ: PGNY) reported Q4 2024 financial results with revenue of $298.4 million, up 10.6% year-over-year. The fertility benefits company generated quarterly operating cash flow of $52.2 million.
Key Q4 metrics include: fertility benefit services revenue of $187.5M (+9%), pharmacy benefit services revenue of $111.0M (+13%), gross profit of $63.4M (+11%), and net income of $10.5M. The company ended 2024 with 473 clients, up from 392 in 2023.
For full-year 2024, Progyny achieved revenue of $1.17B (+7.2%), net income of $54.3M, and Adjusted EBITDA of $198.8M. The company issued 2025 guidance projecting revenue between $1.175B-$1.225B (+1-5%) and expects to serve over 530 clients representing approximately 6.7 million covered lives.
Progyny (Nasdaq: PGNY), a fertility, family building, and women's health benefits solution provider, has scheduled its Q4 and Full Year 2024 financial results announcement for February 27, 2025, after market close. The company will host a conference call at 4:45 p.m. ET, accessible to U.S. participants at 1.866.825.7331 and international participants at 1.973.413.6106 (passcode: 265484).
An audio replay will be available until March 6, 2025, and can be accessed at 1.800.332.6854 (U.S.) or 1.973.528.0005 (international). A live webcast and recording will be available on the company's investor relations website.
Progyny (NASDAQ: PGNY) has announced the acquisition of BenefitBump, a parental leave benefits navigation program, expanding its fertility and family building services portfolio. The acquisition aims to address the needs of 90% of parents seeking greater support in managing work-home responsibilities.
The enhanced service suite will include a clinical social worker-led parental wellness program, comprehensive parental leave and benefits navigation, care and resource navigation for child behavior concerns and neurodiverse care, and clinician-facilitated peer support groups. This integration extends Progyny's existing services across preconception, fertility, pregnancy, postpartum, and menopause care.
The acquisition is designed to reduce member stress, improve recruitment, return-to-work and retention rates, and foster proactive child and family health by eliminating fragmentation in family support services.
Progyny (Nasdaq: PGNY) has appointed Debra Morris, a 30-year healthcare industry veteran, to its board of directors effective January 16, 2025. Morris, who currently serves as President of AccessHope, brings extensive experience in healthcare operations and financial management. She previously held the position of EVP and CFO at Apria Healthcare.
Morris will serve on the Compensation Committee and brings personal experience with infertility along with professional expertise in scaling organizations, healthcare systems, payment models, and operational efficiency. CEO Pete Anevski highlighted Morris's ability to navigate periods of rapid growth as particularly valuable for Progyny's continued expansion of family building and women's healthcare solutions.
Progyny (Nasdaq: PGNY), a leader in fertility, family building, and women's health benefits, announced its participation in the 43rd Annual JP Morgan Healthcare Conference. The company plans to discuss updated financial expectations for the fourth quarter and full year ending December 31, 2024. In the November earnings call, Progyny had anticipated flat to declining member activity for Q4 compared to Q3 2024, due to earlier variability.
However, CEO Pete Anevski reported improved member activity and treatment volume, leading Progyny to expect Q4 results for revenue, net income, and Adjusted EBITDA to be slightly above previous guidance ranges. Anevski will present at the conference on January 14, 2025, at 7:30 a.m. PT / 10:30 a.m. ET, followed by a breakout session with key executives. A live audiocast and replay will be available on Progyny's investor relations website.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
